5 completed, 2 unknown. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Unknown 2 |
| Phase 2 | 2 | Unknown 2 |
Follow End-Stage Kidney Disease: new trials by email Literature Review of End-Stage Kidney Disease trials Research Report on End-Stage Kidney Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010) MK-5684, Prednisone, Fludrocortisone acetate - Kidney Failure, Chronic, End-Stage Kidney Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2025-04-07 | 2025-10-23 |
| A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants AZD4144 - Renal Impairment, End-stage Kidney Disease | Phase 1 | Completed | AstraZeneca | 41 | 2024-11-18 | 2026-04-07 |
| Transplantation of Uncontrolled DCD Kidneys REconditioned by a Novel Ex-VIVo Perfusion MEthod uDCD treatment - End-Stage Kidney Disease | Phase 1 / Phase 2 | Unknown | Sahlgrenska University Hospital | 8 | 2023-08-21 | 2023-01-31 |
| Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD Empagliflozin, Placebo - End-stage Kidney Disease, Kidney Disease, Chronic | Phase 1 | Completed | University of Utah | 62 | 2023-03-21 | 2025-08-12 |
| A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011) MK-2060, Placebo - End-Stage Renal Disease, End-Stage Kidney Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2023-02-08 | 2025-09-10 |
| Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease colon lotion - Chronic Kidney Failure, End-Stage Kidney Disease | Phase 1 / Phase 2 | Unknown | Pang Peng | 20 | 2017-05-15 | 2018-05-30 |
| Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers Atorvastatin (Lipitor) - End-Stage Kidney Disease | Phase 1 | Completed | University of Chicago | 20 | 2005-05-01 | 2013-01-10 |
Kidney Failure, Chronic (7) · Renal Insufficiency (2) · Renal Insufficiency, Chronic (2) · Kidney Diseases (1)
Chronic Disease (7) · Disease Attributes (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Male Urogenital Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Kidney Diseases (6) · Renal Insufficiency (5) · Renal Insufficiency, Chronic (5)
Atorvastatin (1) · Prednisone (1) · empagliflozin (1) · fludrocortisone acetate (1)
Merck Sharp & Dohme LLC (2) · AstraZeneca (1) · Pang Peng (1) · Sahlgrenska University Hospital (1) · University of Chicago (1) · University of Utah (1)
United States (4) · Bulgaria (1) · China (1) · Romania (1)
Bao Kun (1) · Chen X Yin, Ph.D (1) · Pang Peng (1) · Pradeep Kadambi, MD (1)
R01DK131265 (1)